News Search Results
Apr 15, 2025, 12:09 ET Bladder Cancer Advocacy Network Announces National Presenting Sponsorships by Ferring Pharmaceuticals and the Astellas/Pfizer Alliance for the 2025 Walks to End Bladder Cancer
committed to turning innovative science into VALUE for patients. They provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through their research and development programs, they are pioneering new healthcare solutions for diseases
More news about: The Bladder Cancer Advocacy Network
Apr 15, 2025, 08:11 ET AMSURG Continues Growth With Acquisition of Pinnacle Surgery Center
health systems, the organization delivers high-quality patient care across a diverse spectrum of medical specialties, including gastroenterology, ophthalmology and orthopedics. Guided by its core values — Care Deeply, Champion Excellence, Cultivate Integrity and Celebrate Teamwork — AMSURG is committed
More news about: AMSURG Corporation
Apr 15, 2025, 08:01 ET Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept).
More news about: Biocon Biologics Ltd.
Apr 14, 2025, 20:51 ET U.S. FDA grants interchangeable designation to YUFLYMA® (adalimumab-aaty), Celltrion's biosimilar to Humira® (adalimumab)
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
Apr 14, 2025, 11:45 ET Parker Waichman LLP Represents Victim Diagnosed with NAION after Using Ozempic
concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from
More news about: Parker Waichman LLP
Apr 14, 2025, 08:15 ET Hoot Launches Patient Education Automation to Help Ophthalmologists Increase Premium IOL Conversion Rates
2025 /PRNewswire/ -- Hoot Health, Inc., a leader in specialty medical marketing automation, today announced the launch of Hoot Ophthalmology, a breakthrough platform designed to help cataract surgeons increase conversions to premium intraocular lenses (IOLs) through early, automated
More news about: Hoot Health, Inc.
Apr 14, 2025, 07:00 ET InMode to Report First Quarter 2025 Financial Results and Hold Conference Call on April 28, 2025, Expects Q1 Revenue Between $77.2M-$77.5M, Reiterates FY 2025 Revenue Guidance Between $395M-$405M
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com. Forward-Looking
More news about: InMode Ltd.
Apr 10, 2025, 18:00 ET Alabama Ophthalmology Associates Provides Notice Following Data Security Incident
BIRMINGHAM, Ala., April 10, 2025 /PRNewswire/ -- Alabama Ophthalmology Associates ("AOA") experienced a data security incident that involved personal and / or protected health information belonging to certain current
More news about: Alabama Ophthalmology Associates
Apr 10, 2025, 11:31 ET Healthegy Joins Forces with Cambridge Innovation Institute
Cambridge Innovation Institute Expands Event Coverage via Healthegy to Include Aesthetics, Retina, and Ophthalmology Conferences NEEDHAM, Mass., April
More news about: Cambridge Innovation Institute
Apr 10, 2025, 10:30 ET US Ablation Technology Market worth US$3.87 billion by 2030 with 9.6% CAGR | MarketsandMarkets™
treatment, and supportive regulations. By Based on application, the US ablation technology market is segmented into CVDs, cancer, ophthalmology, pain management, OB/gyn, urology, orthopaedics, cosmetic/aesthetic, and other applications. Some key factors propelling the segment expansion are
More news about: MarketsandMarkets
Apr 10, 2025, 08:37 ET Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
Japan. It's pipeline has several biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social
More news about: Biocon Biologics Ltd.
Apr 10, 2025, 06:45 ET Mallinckrodt plc to Report Earnings Results for First Quarter 2025
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic
More news about: Mallinckrodt plc
Apr 09, 2025, 13:12 ET The Inner Circle acknowledges, Michael C. Stiles, MD as a 2025 Pinnacle Lifetime Member
contributions to Ophthalmology. Dr. Michael C. Stiles, a leading surgical ophthalmologist with a distinguished career in cataract and glaucoma surgeries, continues to make significant contributions to both his patients and the field of ophthalmology. With a private
More news about: The Inner Circle
Apr 08, 2025, 06:00 ET Quad-C Management Completes the Sale of PRISM Vision to McKesson
PRISM Vision is a provider of general ophthalmology and retina management services. The practices include more than 180 providers, 91 office locations and seven ambulatory surgery centers. The company
More news about: Quad-C Management, Inc.
Apr 04, 2025, 09:08 ET NYU Langone Neurologists Present Latest Clinical Findings & Research at AAN 2025
C146 - Neuro-ophthalmology 2: Optic Neuritis, Visual Fields, and Anisocoria. Seminar: Treatment of Pediatric Multiple Sclerosis in the Current Era
More news about: NYU Grossman School of Medicine and NYU Langone Health
Apr 04, 2025, 08:15 ET Music Icon Art Garfunkel Opens Up About His Experience with Psoriasis for The First Time in Partnership with Sun Pharma
company in the U.S. as well as Global Emerging Markets. Sun's high-growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharmaceutical Industries Inc., USA (Sun Pharma)
Apr 04, 2025, 08:00 ET Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Keswani will continue to serve on ImmunoBrain's board of directors. Before that, he was Senior Vice President and R&D Head for Neuroscience, Ophthalmology and Rare Diseases at Hoffman La Roche. Earlier, he was Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb,
More news about: Neurocrine Biosciences, Inc.
Apr 03, 2025, 15:49 ET Malvina Eydelman, MD, Appointed CEO of Collaborative Community on Ophthalmic Innovation (CCOI)
commitments include serving in an advisory/editorial board member capacity to JAMA Ophthalmology, Asia-Pacific Academy of Ophthalmology AI and Digital Innovation committee, Eye & Contact Lens Journal, Ophthalmology Futures Forums, EnVision Summit Program Committee, and acting as a Visionary Innovation
More news about: The Collaborative Community on Ophthalmic Innovation (CCOI)
Apr 03, 2025, 10:17 ET NorthStar VETS Partners with Philadelphia Animal Specialty & Emergency (PASE) to Enhance Veterinary Care for the Community
advanced care in a wide range of specialties, including emergency, critical care, internal medicine, medical and radiation oncology, neurology, ophthalmology, cardiology, surgery, and more. For more information, visit northstarvets.com About Philadelphia Animal Specialty & Emergency (PASE)
More news about: NorthStar VETS
Apr 02, 2025, 13:35 ET Schwarzman Animal Medical Center Completes Phase II of 83,000 Square-Foot, $125 Million Transformative Center-Wide Expansion & Renovation
$125 million dollar transformation with the anticipated opening of the new Emergency Room, Cardiology, Radiology, Ophthalmology, Neurology and Internal Medical Services. Originally founded in 1910, 115 years ago, AMC broke ground in 2021 and will complete construction in
More news about: Schwarzman Animal Medical Center
Apr 02, 2025, 12:36 ET Avisi Technologies Presents Positive Six-Month Clinical Data for VisiPlate® Aqueous Shunt at the American Glaucoma Society
Commentary Joseph F. Panarelli, MD, Director of Glaucoma Services at NYU Langone Health and Professor of Ophthalmology at NYU Grossman School of Medicine, commented, "These results are very exciting and I'm anticipating having VisiPlate be a part of my practice in
More news about: Avisi Technologies
Apr 02, 2025, 11:00 ET US Clinical Trial Services Market worth US$39.61 billion by 2030 with 9.2% CAGR | MarketsandMarkets™
system (CVS) disorders, metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women's health, and other therapeutic areas. In 2024, the oncology segment dominated the US clinical
More news about: MarketsandMarkets
Apr 02, 2025, 10:00 ET Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor
R&D engine, including 12 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for market approval,
More news about: Mabwell
Apr 02, 2025, 09:00 ET UWorld Grants Over $75,000 in Financial Support and Product Scholarships Through Its Barry Goldwater Partnership
Healzer, a junior at Stanford University, pursuing an interdisciplinary M.D./Ph.D. in molecular biology and ophthalmology with eye research interests in glaucoma-related blindnessArul Goel, a sophomore at the University
More news about: UWorld
Apr 01, 2025, 11:00 ET Applications for the American Board of Medical Specialties 2025-2026 Visiting Scholars Program are Now Available
following ABMS Member Boards: Allergy and Immunology, Dermatology, Emergency Medicine, Internal Medicine (Foundation), Obstetrics and Gynecology, Ophthalmology, Orthopaedic Surgery, Physical Medicine and Rehabilitation, Radiology, Surgery, and Urology. Interested researchers can learn about the ABMS
More news about: American Board of Medical Specialties